Brief: Akeso Says Anniko (Penpulimab) Granted Marketing Approval By National Medical Products Administration
15/01/2023 23:24
Jan 16 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK :
* ANNIKO (PENPULIMAB) GRANTED MARKETING APPROVAL BY NATIONAL
MEDICAL PRODUCTS ADMINISTRATION IN CHINA
* MARKETING APPROVAL OF ANNIKO PENPULIMAB) COMBINED WITH
CHEMOTHERAPY AS FIRST LINE TREATMENT OF LOCALLY ADVANCED OR
METASTATIC SQUAMOUS NSCLC
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals